| Name | Title | Contact Details |
|---|
Hanna Instruments is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
It`s good to be home! Jet Health is a provider of skilled home health, hospice, personal care, and companion services. Founded in April 2016, Jet Health is building a national platform through organic growth, strategic acquisitions, and de novo build-outs in target markets. These markets are typically mid-sized cities that have under served and growing Medicare populations. Jet Health leverages local brands and operating expertise while sharing best practices across its companies and centralizes traditional back office functions. The company believes that its four cornerstones: superior service, clinical excellence, compliant business practices and an employee centric environment, provide a solid foundation upon which to build a successful company in the home health marketplace.
Windsor Health Plan, Inc. is a Medicare Advantage plan with a Medicare contract, and a Medicare-approved Part D Sponsor, whose core purpose is to improve health and well being, peace of mind and financial security for our members when navigating health care coverage options. A partnership between Windsor Health Plan and Sterling Life Insurance Company since 2011, the organization can now provide more resources, member support and plan options for Medicare Advantage beneficiaries and is a leader in the provision of health care to Medicare- and Medicaid-eligible members seeking to enhance their quality of life. Windsor Health Plan manages government sponsored health plans and provides specialty managed care services to insurance providers and to health care providers. Windsor Health Plan is a division of Windsor Health Group, with corporate offices in Atlanta and operational offices in Nashville, Tenn. and Bellingham, Wash., as well as regional offices throughout the United States.
Croes Communications, Inc is a Oak Hall, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Unlike traditional approaches that only address symptoms, Cardionomic addresses the conditions root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality. This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life. Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.